Joseph Spernyak
Facility
Department of Cell Stress Biology
Roswell Park Cancer Institute
United States of America
Biography
Dr. Spernyak has been involved in a broad range of research projects incorporating the use of magnetic resonance imaging (MRI) for studying small animal model of disease. His recent interests have focused primarily in three areas, a) development and assessment of novel MRI/PDT contrast agents for the purpose of combining imaging and therapy within a single compound, b) use of MRI to non-invasively characterize changes in tumor microvasculature arising from anti-cancer therapies, and c) application of balanced, steady-state free precession imaging for efficient and accurate measurement of tissue MR relaxation rates.
Research Interest
Magnetic resonance imaging in animal models of disease
Publications
-
Chintala S, Vaughan MM, Horowitz JM, Meeder BA, Spernyak JA, et al. (2010) The Vps33a gene regulates behavior and cerebellar Purkinje cell number. Brain research 1266: 18-28
-
Spernyak JA, Mazurchuk R, Batt C, Missert JR, Turowski S, (2010) Hexylether derivative of pyropheophorbide-a (HPPH) on conjugating with 3gadolinium(III) aminobenzyldiethylenetriaminepentaacetic acid shows potential for in vivo tumor imaging (MR, Fluorescence) and photodynamic therapy. Bioconjugate chemistry 21: 828-835
-
Goswami LN, White WH, Spernyak JA, Ethirajan M, Chen Y, et al. (2010) Synthesis of Tumor-avid Photosensitizer-Gd(III)DTPA conjugates: impact of the number of gadolinium units in T1/T2 relaxivity, intracellular localization, and photosensitizing efficacy. Bioconjugate chemistry 21: 816-827
